Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kymera Therapeutics, Inc.

23.69
-2.6700-10.13%
Post-market: 23.690.00000.00%18:21 EDT
Volume:709.39K
Turnover:17.14M
Market Cap:1.54B
PE:-7.94
High:25.07
Open:24.64
Low:23.64
Close:26.36
Loading ...

Earnings Flash (KYMR) Kymera Therapeutics Posts Q4 Revenue $7.4M, vs. FactSet Est of $14.4M

MT Newswires Live
·
27 Feb

Kymera Therapeutics reports Q4 EPS (88c), consensus (79c)

TIPRANKS
·
27 Feb

Kymera Therapeutics Q4 2024 GAAP EPS $(0.88) Misses $(0.78) Estimate, Sales $7.39M Miss $11.82M Estimate

Benzinga
·
27 Feb

BRIEF-Kymera Therapeutics Q4 EPS USD -0.88 Vs. IBES Estimate USD -0.77

Reuters
·
27 Feb

Kymera Therapeutics Q4 EPS USD -0.88 VS. Ibes Estimate USD -0.77

THOMSON REUTERS
·
27 Feb

Kymera Therapeutics: Well-Capitalized With $851 Mln in Cash as of Dec 31, 2024, and Runway Into Mid-2027

THOMSON REUTERS
·
27 Feb

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

GlobeNewswire
·
27 Feb

Kymera Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview

Reuters
·
25 Feb

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

GlobeNewswire
·
20 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
20 Feb

Naya Biosciences Announces Nomination of New Board Members

THOMSON REUTERS
·
19 Feb

NAYA Biosciences Announces Nomination of New Board Members

GlobeNewswire
·
19 Feb

Kymera Therapeutics Price Target Maintained With a $60.00/Share by Stephens & Co.

Dow Jones
·
22 Jan

Conviction stock-picking drives biotech success: a biotech market review of 2024

LiveWire
·
17 Jan

Kymera Therapeutics (KYMR) Gets a Buy from Truist Financial

TIPRANKS
·
16 Jan

Bank of America Securities Remains a Hold on Kymera Therapeutics (KYMR)

TIPRANKS
·
16 Jan

Kymera Provides Pipeline Objectives for 2025, Stock Gains

Zacks
·
16 Jan

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?

Zacks
·
15 Jan

Kymera Therapeutics Unveils 2025 Strategy and Trials

TIPRANKS
·
15 Jan

Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments

GuruFocus.com
·
15 Jan